BRIGHT MINDS BIOSCIENCES INC. (DRUG)
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Bright Minds Biosciences Inc.
NASDAQ:DRUGHealthcare · Biotechnology
-0.40%$52.48
AH Close$52.40-0.15%vs close
AH Close$52.40-0.15%vs close
Mkt Cap$517.67M
Float6.2M
O/S9.86M
Inst Own94.4%
SI14.2%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$8.74M
Total Assets$60.32M
Free Cash Flow-$6.21M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$90K
Total Equity$58.62M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:5Reverse splitJul 14, 20235 shares → 1
Balance Sheet Details
Assets$60.32M
Liabilities$1.7M
Accounts Receivable$295K
Accounts Payable$1.22M
Inventory$0
PP&E (Net)$80K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $7.92M | $843K | $3.57M | $8.7M | $4.51M | $254K | $90K |
| Selling, General, and Administrative | $1.83M | $1.03M | $1.57M | $1.82M | $1.65M | $86K | $79K |
| Other | $206K | $141K | $133K | $174K | $0 | $0 | $0 |
| Total Operating Expenses | $9.96M | $2.02M | $5.28M | $10.7M | $6.16M | $339K | $169K |
| Operating Income (EBIT) | -$9.96M | -$2.02M | -$5.28M | -$10.7M | -$6.16M | -$339K | -$169K |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $1.09M | $22K | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $1.22M | $15K | $10K | $7K | -$20K | -$4K | $0 |
| Income Before Tax (EBT) | -$8.74M | -$2M | -$5.27M | -$10.69M | -$6.18M | -$343K | -$169K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$8.74M | -$2M | -$5.27M | -$10.69M | -$6.18M | -$343K | -$169K |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -1.78 | -0.65 | -1.98 | -6.15 | -4.74 | -0.38 | -0.06 |
| Diluted EPS | -1.78 | -0.65 | -1.98 | -6.15 | -4.74 | -0.38 | -0.06 |
| Weighted Average OS | 6.88M | 4.31M | 3.72M | 2.47M | 1.79M | 1.28M | 1.28M |
| EBITDA | -$8.68M | -$1.95M | -$5.22M | -$10.69M | -$20K | $0 | $0 |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $59.24M | $4.09M | $4.82M | $8.31M | $14.12M | $572K | $57K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $59.24M | $4.09M | $4.82M | $8.31M | $14.12M | $572K | $57K |
| Accounts Receivable | $295K | $36K | $26K | $111K | $79K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $60.24M | $4.28M | $4.87M | $8.54M | $14.32M | $628K | $57K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $80K | $84K | $47K | $99K | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $1K | $1K | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $1 | $1K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $24K | $715 | $59K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | -$24K | -$715 | $0 |
| Total Long-Term Assets | $80K | $84K | $47K | $99K | $1K | $1K | $60K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $60.32M | $4.36M | $4.92M | $8.64M | $14.32M | $629K | $117K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $1.22M | $291K | $130K | $891K | $426K | $99K | $26K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $1.67M | $378K | $201K | $1.05M | $456K | $108K | $26K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $29K | $28K | $0 | $51K | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.7M | $406K | $201K | $1.1M | $456K | $108K | $26K |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $88.06M | $25.31M | $24.23M | $23.03M | $19.35M | $701K | $147K |
| Retained Earnings | -$33.28M | -$24.54M | -$22.54M | -$17.27M | -$6.58M | -$399K | -$56K |
| Comprehensive Income & Other | $3.84M | $2.86M | $2.43M | $1.77M | $1.12M | $115K | -$59K |
| Other Stockholders' Equity | $3.84M | $3.19M | $3.02M | $1.77M | $1.09M | $220K | -$1 |
| Total Equity | $58.62M | $3.96M | $4.71M | $7.53M | $13.86M | $521K | $91K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $60.32M | $4.36M | $4.92M | $8.64M | $14.32M | $629K | $117K |
| Supplementary Data | |||||||
| Total Debt | $90K | $85K | $53K | $100K | $0 | $0 | $0 |
| Net Debt | -$59.15M | -$4M | -$4.77M | -$8.21M | -$14.12M | -$572K | -$57K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Operating Activities | |||||||
| Net Income | -$8.74M | -$2M | -$5.27M | -$10.69M | -$6.18M | -$343K | -$56K |
| Depreciation & Amortization | $55K | $52K | $52K | $4K | $6.16M | $339K | $169K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $2.27M | $600K | $823K | $625K | $629K | $115K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$259K | -$9K | $85K | -$33K | -$79K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Working Capital | $656K | $38K | -$758K | $550K | $297K | $22K | $26K |
| Total Working Capital Change | $397K | $28K | -$673K | $517K | $219K | $22K | $26K |
| Other Non-Cash Items | -$198K | -$844 | $47K | -$162K | -$6.06M | -$339K | -$169K |
| Net Cash from Operating | -$6.21M | -$1.32M | -$5.02M | -$9.71M | -$5.23M | -$206K | -$30K |
| Investing Activities | |||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | |||||||
| Debt Repaid | $72K | $64K | $62K | $5K | - | - | - |
| Common Stock Issuance | $61.47M | $643K | $870K | $2.88M | $19.82M | $720K | $87K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$257K | $0 | $756K | $835K | -$1.21M | $0 | $262K |
| Net Cash from Financing | $61.14M | $579K | $1.56M | $3.71M | $18.62M | $720K | $87K |
| Forex Effect | $223K | $8K | -$32K | $185K | $160K | $0 | $0 |
| Net Change in Cash | $55.15M | -$734K | -$3.49M | -$5.81M | $13.55M | $514K | $57K |
| Supplementary Data | |||||||
| Operating Cash Flow | -$6.21M | -$1.32M | -$5.02M | -$9.71M | -$5.23M | -$206K | -$30K |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6.21M | -$1.32M | -$5.02M | -$9.71M | -$5.23M | -$206K | -$30K |
| Cash at Beginning | $4.09M | $4.82M | $8.31M | $14.12M | $572K | $57K | $0 |
| Cash at End | $59.24M | $4.09M | $4.82M | $8.31M | $14.12M | $572K | $57K |